Nguyen Nam P, Frank Cheryl, Moltz Candace C, Vos Paul, Smith Herbert J, Bhamidipati Prabhakar V, Karlsson Ulf, Nguyen Phuc D, Alfieri Alan, Nguyen Ly M, Lemanski Claire, Chan Wayne, Rose Sue, Sallah Sabah
Department of Radiation Oncology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75216, USA.
Radiother Oncol. 2006 Sep;80(3):302-6. doi: 10.1016/j.radonc.2006.07.031. Epub 2006 Aug 4.
We would like to assess the prevalence of aspiration before and following chemoradiation for head and neck cancer.
We reviewed retrospectively the Modified Barium Swallow (MBS) in 63 patients who underwent concurrent chemotherapy and radiation for head and neck cancer. MBS was performed prior to treatment to determine the need for immediate gastrostomy tube placement. MBS was repeated following treatment to assess the safety of oral feeding prior to removal of tube feeding. All patients were cancer free at the time of the swallowing study. No patient had surgery. Dysphagia severity was graded on a scale of 1-7. Tube feedings were continued if patients were diagnosed to have severe aspiration (grade 6-7) or continued weight loss. Patients with abnormal swallow (grade 3-7) received swallowing therapy following MBS.
Before treatment, there were 18 grade 1, 18 grade 2, 9 grade 3, 8 grade 4, 3 grade 5, 3 grade 6, and 4 grade 7. Following chemoradiation, at a median follow-up of 2 months (1-10 months), one patient had grade 1, eight patients had grade 2, nine patients had grade 3, eight patients had grade 4, 13 patients had grade 5, seven patients had grade 6, and 11 patients had grade 7. Six patients died from aspiration pneumonia (one before, three during, and two post-treatment), and did not have the second MBS. Overall, 37/63 (59%) patients developed aspiration, six of them (9%) fatal. If we excluded the 10 patients who had severe aspiration at diagnosis and the six patients who died from pneumonia, the prevalence of severe aspiration was 33% (21/63).
Aspiration remained a significant morbidity following chemoradiation for head and neck cancer. Its prevalence is underreported in the literature because of its often silent nature. Diagnostic studies such as MBS should be part of future head and neck cancer prospective studies to assess the prevalence of aspiration, and for rehabilitation.
我们希望评估头颈部癌放化疗前后误吸的发生率。
我们回顾性分析了63例接受头颈部癌同步放化疗患者的改良吞钡检查(MBS)结果。在治疗前进行MBS以确定是否需要立即放置胃造瘘管。治疗后重复进行MBS以评估在停止管饲前经口进食的安全性。所有患者在吞咽研究时均无癌症。所有患者均未接受手术。吞咽困难严重程度按1 - 7级进行分级。如果患者被诊断为严重误吸(6 - 7级)或持续体重减轻,则继续进行管饲。吞咽异常(3 - 7级)的患者在MBS后接受吞咽治疗。
治疗前,有18例1级、18例2级、9例3级、8例4级、3例5级、3例6级和4例7级。放化疗后,中位随访2个月(1 - 10个月),1例患者为1级,8例患者为2级,9例患者为3级,8例患者为4级,13例患者为5级,7例患者为6级,11例患者为7级。6例患者死于吸入性肺炎(1例在治疗前,3例在治疗期间,2例在治疗后),未进行第二次MBS。总体而言,37/63(59%)的患者发生了误吸,其中6例(9%)死亡。如果排除诊断时即有严重误吸的10例患者和死于肺炎的6例患者,严重误吸的发生率为33%(21/63)。
头颈部癌放化疗后误吸仍然是一种严重的并发症。由于其通常无症状性,其发生率在文献中报道不足。像MBS这样的诊断性研究应成为未来头颈部癌前瞻性研究的一部分,以评估误吸的发生率并用于康复治疗。